\
&
Contact us
This was 1 year ago
Locationvirtual
ProgrammesThis workshop is co-organised by the OECD Global Science Forum and the European Strategy Forum for Research Infrastructures (ESFRI) and is dedicated to
Participation to the workshop is free. It is required to register. A short introduction, the full agenda and the registration link are available via the announcement of the workshop on the RICH NCP network website.
Programme in brief
10:00-10:10 Introduction (OECD and ESFRI: rationale for this workshop, workshop organisation and expectations)
10:10-11:00 Needs and expectations from decision-makers regarding the need for better data on RI-funding
11:15-11:30 Break
11:30-13:00 Current challenges in measuring public expenditures on RIs and lessons learned from existing data gathering at regional/international level
13:00-13:30 Lunch Break
13:30-15:00 Gathering public expenditures data on RIs
15:00-15:45 Possible options to standardise public expenditure on RIs data collection
15:45-16:00 Closing words and follow up
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.